Evidence map›Paper›PMID 38722955›Full record

ArticlePloS one2024

Mutation of SIVA, a candidate metastasis gene identified from clonally related bilateral breast cancers, promotes breast cancer cell spread in vitro and in vivo.

Anke Vermehren-Schmaedick, Myron Peto, Wendy Wagoner, Kami E Chiotti, Elizabeth Ramsey, Xiaoyan Wang, Shauna Rakshe, Jessica Minnier, Rosalie Sears, Paul Spellman and 1 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anke Vermehren-SchmaedickVeterans Administration Portland Health Care System, Portland, Oregon, United States of America.ORCID 0000-0003-3788-1406
Myron PetoKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
Wendy WagonerVeterans Administration Portland Health Care System, Portland, Oregon, United States of America.
Kami E ChiottiMolecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States of America.
Elizabeth RamseyVeterans Administration Portland Health Care System, Portland, Oregon, United States of America.
Xiaoyan WangMolecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States of America.
Shauna RaksheKnight Cancer Institute, Biostatistics Shared Resource, Oregon Health & Science University, Portland, Oregon, United States of America.
Jessica MinnierKnight Cancer Institute, Biostatistics Shared Resource, Oregon Health & Science University, Portland, Oregon, United States of America.ORCID 0000-0002-3527-2757
Rosalie SearsKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
Paul SpellmanKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
Shiuh-Wen LuohVeterans Administration Portland Health Care System, Portland, Oregon, United States of America.

Funding

BLRD VA I01 BX002236
6 · The paper itself

Abstract

Metastasis is the most dreaded outcome after a breast cancer diagnosis, and little is known regarding what triggers or promotes breast cancer to spread distally, or how to prevent or eradicate metastasis effectively. Bilateral breast cancers are an uncommon form of breast cancers. In our study, a percentage of bilateral breast cancers were clonally related based on copy number variation profiling. Whole exome sequencing and comparative sequence analysis revealed that a limited number of somatic mutations were acquired in this "breast-to-breast" metastasis that might promote breast cancer distant spread. One somatic mutation acquired was SIVA-D160N that displayed pro-metastatic phenotypes in vivo and in vitro. Over-expression of SIVA-D160N promoted migration and invasion of human MB-MDA-231 breast cancer cells in vitro, consistent with a dominant negative interfering function. When introduced via tail vein injection, 231 cells over-expressing SIVA-D160N displayed enhanced distant spread on IVIS imaging. Over-expression of SIVA-D160N promoted invasion and anchorage independent growth of mouse 4T1 breast cancer cells in vitro. When introduced orthotopically via mammary fat pad injection in syngeneic Balb/c mice, over-expression of SIVA-D160N in 4T1 cells increased orthotopically implanted mammary gland tumor growth as well as liver metastasis. Clonally related bilateral breast cancers represented a novel system to investigate metastasis and revealed a role of SIVA-D160N in breast cancer metastasis. Further characterization and understanding of SIVA function, and that of its interacting proteins, may elucidate mechanisms of breast cancer metastasis, providing clinically useful biomarkers and therapeutic targets.

Indexed as

Apoptosis Regulatory ProteinsBreast NeoplasmsNeoplasm MetastasisAnimalsCell Line, TumorCell MovementDNA Copy Number VariationsFemaleHumansMiceMice, Inbred BALB CMutationNeoplasm InvasivenessApoptosis Regulatory ProteinsSIVA1 protein, human

Identifiers

PMID38722955
PMCPMC11081324

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.